Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11145541 | 0.86 | NPC1 (0.54) | GRIN2BNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4206100 | 0.75 | HTRA1 (0.53) | — | |
| SCHEMBL18853751 | 0.75 | HTRA1 (0.53) | — | |
| SCHEMBL4196684 | 0.75 | HTRA1 (0.53) | — | |
| SCHEMBL15730122 | 0.75 | HTRA1 (0.53) | — | |
| SCHEMBL15730092 | 0.75 | HTRA1 (0.53) | — | |
| SCHEMBL16608101 | 0.75 | GRIN2B (1.00) | GRIN2BNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL16600721 | 0.75 | GRIN2B (1.00) | GRIN2BNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL23327023 | 0.73 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL31234028 | 0.73 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901336-B2 | Catalysts, methods of making catalysts, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901336-B2 | Catalysts, methods of making catalysts, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130060056-A1 | CATALYSTS, METHODS OF MAKING CATALYSTS, AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060056-A1 | CATALYSTS, METHODS OF MAKING CATALYSTS, AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060056-A1 | CATALYSTS, METHODS OF MAKING CATALYSTS, AND METHODS OF USE | SOD1, CAT, APEX1 | GRIN2B 2708/4885NPC1 1674/4885RAB9A 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.